Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 191

Similar articles for PubMed (Select 16303295)

1.

Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.

Rosenkranz B, Rouzier R, Kruse M, Dobson C, Ayre G, Horowitz A, Fitoussi S.

Respir Med. 2006 Apr;100(4):666-72. Epub 2005 Nov 21.

2.

Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.

Kruse M, Rosenkranz B, Dobson C, Ayre G, Horowitz A.

Pulm Pharmacol Ther. 2005;18(3):229-34.

PMID:
15707858
3.

Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.

Cazzola M, D'Amato M, Califano C, Di Perna F, Calderaro E, Matera MG, D'Amato G.

Clin Ther. 2002 Apr;24(4):595-604.

PMID:
12017404
5.

The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.

Goldkorn A, Diotto P, Burgess C, Weatherall M, Holt S, Beasley R, Siebers R.

Respirology. 2004 Mar;9(1):102-8.

PMID:
14982610
7.
8.
9.

24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.

Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M.

Curr Med Res Opin. 2009 Feb;25(2):463-70. doi: 10.1185/03007990802675096 .

PMID:
19192991
10.

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.

Clin Ther. 2007 Feb;29(2):261-78.

PMID:
17472819
11.

Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma.

Boonsawat W, Charoenratanakul S, Pothirat C, Sawanyawisuth K, Seearamroongruang T, Bengtsson T, Brander R, Selroos O.

Respir Med. 2003 Sep;97(9):1067-74.

PMID:
14509562
12.

Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).

Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gros V, Kottakis J, Bourdeix I.

Respir Med. 2001 Oct;95(10):817-21.

PMID:
11601748
13.

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.

D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J; FOR-INT-03 Study Group.

Chest. 2001 May;119(5):1347-56.

PMID:
11348938
15.

Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.

Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppa G, Thomson M, Andriano K, Kottakis J, Fashola T.

Respiration. 2004 Mar-Apr;71(2):126-33.

16.

Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.

Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G.

Eur J Clin Pharmacol. 1999 Apr;55(2):131-8.

PMID:
10335908
17.

Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.

La Piana GE, Corda L, Bertella E, Montemurro LT, Pini L, Tantucci C.

Int J Chron Obstruct Pulmon Dis. 2011;6:399-405. doi: 10.2147/COPD.S22179. Epub 2011 Jul 12.

18.

Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.

Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K; Formoterol Study Group.

Clin Ther. 2007 Oct;29(10):2167-78. Erratum in: Clin Ther. 2009 Apr;31(4):920.

PMID:
18042473
19.

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.

Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T.

Ther Adv Respir Dis. 2009 Aug;3(4):1-11. doi: 10.1177/1753465809344870. Epub 2009 Sep 4.

PMID:
19734176
20.

Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.

Panettieri RA Jr, MacIntyre N, Sims M, Kerwin E, Fogarty C, Noonan M, Claus R, Andrews WT.

Clin Ther. 2009 Aug;31(8):1716-23. doi: 10.1016/j.clinthera.2009.08.012.

PMID:
19808130
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk